Skip to main content

INO

Stock
Health Care
Biotechnology

Performance overview

INO Price
Price Chart

Forward-looking statistics

Beta
0.99
Risk
85.95%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Inovio Pharmaceuticals Inc is a United States-based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Company info

SectorHealth Care
IndustryBiotechnology
Employees215
Market cap$248.5M

Fundamentals

Enterprise value—
Revenue—
Revenue per employee—
Profit margin—
Debt to equity—

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)—
Dividend per share—
Revenue per share—
Avg trading volume (30 day)—
Avg trading volume (10 day)—
Put-call ratio—

Macro factor sensitivity

Growth-2.4
Credit+6.6
Liquidity-1.0
Inflation-2.1
Commodities-1.0
Interest Rates-1.6

Valuation

Dividend yield0.00%
PEG Ratio—
Price to sales—
P/E Ratio-0.55
Enterprise Value to Revenue—
Price to book—

Upcoming events

Next earnings dayMay 14, 2025
Next dividend day—
Ex. dividend day—

News

Innodata Trades 29% Below 52-Week High: Buy, Sell, or Hold the Stock?

INOD rides Gen AI momentum with major Big Tech deals and a 40% revenue growth forecast, but high valuation raises caution.

Zacks Investment Research (July 18, 2025)
INOD Stock Expands GenAI Offerings: Can it Drive Enterprise Growth?

Innodata expands GenAI offerings as DDS revenue hits $50.8M, driven by Big Tech wins and deeper client ties.

Zacks Investment Research (July 8, 2025)
Is HF Sinclair (DINO) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research (July 8, 2025)
Inovio Pharmaceuticals (INO) Reports Q1 Loss, Tops Revenue Estimates

Inovio Pharmaceuticals (INO) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.74. This compares to loss of $1.31 per share a year ago.

Zacks Investment Research (May 13, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free